![Harry Raftopoulos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Harry Raftopoulos is Senior Vice President & Clinical Research at Eikon Therapeutics, Inc. since 2023.
Formerly, Mr. Raftopoulos was a Scientific Advisor at FutuRx Ltd.
| Sociétés | Poste | Début |
|---|---|---|
| EIKON THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx invests in companies located in Israel. The firm focuses on sectors such as health technology and technology services with an investment size of ILS 3 million. It participates in seed stage transactions and also makes follow on investment. | Consultant / Advisor | 01/04/2023 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 2 |
|---|---|
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx invests in companies located in Israel. The firm focuses on sectors such as health technology and technology services with an investment size of ILS 3 million. It participates in seed stage transactions and also makes follow on investment. | Finance |
Eikon Therapeutics, Inc.
 Eikon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical biopharmaceutical and drug discovery company | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
